Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multinational randomized open-label Phase 3 trial of Mim8 in haemophilia A with or without inhibitors
KCT0005993Phase 3Completed
- Sponsor
- Novo Nordisk
- Start
- Dec 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of denecimig in hemophilia A, sponsored by Novo Nordisk. Started Dec 2021; status: completed.
02
Drugs
denecimig
03
Conditions
hemophilia A
Beyond the preview
Go deeper on KCT0005993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0005993.